Colorectal Cancer Therapeutics Market Explored by GBI Research in Its New Insightful Research Report Published at MarketPublishers.com

16 Mar 2017 • by Natalie Aster

LONDON – Today, therapeutic options for colorectal cancer (CRC) differ between the two treatment settings, with therapies for adjuvant CRC aimed to prevent disease re-occurrence and therapies for advanced conditions aimed to slow the disease progression at the same time maintaining a patient’s quality of life.

Targeted therapies have already shown signs of extending the lifespan of metastatic CRC patients in comparison to chemotherapy-only regimens. Still, there remains high unmet needs to improve the efficacy of treatments and also to extend survival for patients. Furthermore, there are unmet needs for patients with KRAS mutation-positive CRC, as certain presently marketed therapies are not recommended for them.

In-demand topical research report “Colorectal Cancer - Heat Map and Analysis” worked out by GBI Research contains a detailed analysis of the current therapeutic landscape of the world’s colorectal cancer market and also includes an all-round overview of clinical benchmarks. Moreover, the report covers the anticipated changes in the market as well as examines the therapeutic pipeline of colorectal cancer. The research report discusses promising pipeline therapies, delves into the changing market scenario, reviews the currently approved therapies for CRC cancer, identifies the key unmet needs in the field, points out the major factors influencing the development of the CRC cancer market as well as gives projections for the world’s colorectal cancer therapeutics market up till 2022.

Other Cutting-Edge Research Reports by GBI Research Include:

A full list of the research reports prepared by this publisher are offered in the GBI Research catalogue at MarketPublishers.com.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com